
Artery Therapeutics
Artery Therapeutics, Inc. (Artery), a clinical-stage biotechnology company headquartered in the San Francisco Bay area, develops proprietary therapeutics for mainly neurodegenerative diseases, including apolipoprotein E4 (APOE4)-driven dementia and Alzheimer's disease. The company's novel peptide library is derived from ApoE. Its safe and effective peptides are designed to manipulate the ABCA1 (ATP-binding cassette) transporter, thereby altering cell membrane composition and functionality of monocyte-macrophage cells, including glial cells in the brain. In a Phase 1 study of 66 subjects with and without the APOE4 risk factor, CS6253 demonstrated a favorable safety profile and pharmacokinetics. Artery Therapeutics is partially sponsored by NIH-NIA and Alzheimer’s Association Part the Cloud.